Skip to main content

Advertisement

SpringerLink
Log in

Preventing Breast, Ovarian Cancer in BRCA Carriers: Rational of Prophylactic Surgery and Promises of Surveillance

  • Editorial
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCES

  1. Jemal A, Tiwari RC, Murray T. Cancer Statistics. CA Cancer J Clin 2004; 54:8–29.

    Article  PubMed  Google Scholar 

  2. Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process, 2004. (Accessed July 9, 2004, at http://www.ahrq.gov/clinic/ajpmsuppl/harris3.htm.)

  3. King MC, Marks JH, Mandell JB; New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302:643–6.

    Article  PubMed  CAS  Google Scholar 

  4. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004; 22:1055–62.

    Article  PubMed  Google Scholar 

  5. Kriege M, Brekelmans CTM, Boetes C, et al. Efficacy of MRI and mammography for breat-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004; 351:427–37.

    Article  PubMed  CAS  Google Scholar 

  6. Hogg R, Friedlander M. Biology of epithelial ovarian cancer: implications for screening women at high genetic risk. J Clin Oncol 2004; 22:1315–27.

    Article  PubMed  Google Scholar 

  7. Armstrong K, Sanford Schwartz J, Randall T, et al: Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: A decision analysis. J Clin Oncol 2004; 22:1045–54.

    Article  PubMed  Google Scholar 

  8. Narod SA. Modifiers of risk of hereditary breast and ovarian cancer (Review). Nat Rev Cancer 2002; 2:113–23.

    Article  PubMed  Google Scholar 

  9. Couzin J. The twists and turns in BRCA’s path. Science 2003; 302:591–3.

    Article  PubMed  CAS  Google Scholar 

  10. Venkitaraman A. Tracing the network connecting BRCA and Fanconi anaemia proteins. Nat Rev Cancer 2004; 4:266–76.

    Article  PubMed  CAS  Google Scholar 

  11. Nathanson KN, Wooster R, Weber BL. Breast cancer genetics: What we know and what we need. Nat Med 2001; 7:552–6.

    Article  PubMed  CAS  Google Scholar 

  12. Georgiou, I, Fatouros M, Arampatzis I, et al. Evaluating cancer risks in BRCA mutation carriers. Gastric Breast Cancer 2003; 2:45–51.

    Google Scholar 

  13. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998; 62:676–89.

    Article  PubMed  CAS  Google Scholar 

  14. Antoniou A, Pharoah PD, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72:1117–30.

    Article  PubMed  CAS  Google Scholar 

  15. Brose MS, Rebbeck TR, Calzone KA, et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002; 94:1365–72.

    PubMed  CAS  Google Scholar 

  16. Begg CB. On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 2002; 94:1221–6.

    PubMed  Google Scholar 

  17. Roukos DH, Kappas AM, Tsianos E. Role of surgery in the prophylaxis of hereditary cancer syndromes (Editorial). Ann Surg Oncol 2002; 9:607–9.

    Article  PubMed  Google Scholar 

  18. Thompson D, Easton DF. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002; 94:1358–65.

    PubMed  CAS  Google Scholar 

  19. Gruber SB, Petersen GM. Cancer risks in BRCA1 carriers: time for the next generation of studies (Editorial). J Natl Cancer Inst 2002; 94:1344–45.

    PubMed  Google Scholar 

  20. Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345:159–64.

    Article  PubMed  CAS  Google Scholar 

  21. Gabriel SE, Woods JE, O’Fallon WM, et al. Complications leading to surgery after breast implantation. N Engl J Med 1997; 336:677–82.

    Article  PubMed  CAS  Google Scholar 

  22. Guerra AB, Metzinger SE, Bidros RS, et al. Bilateral breast reconstruction with the deep inferior epigastric perforator (DIEP) flap: an experience with 280 flaps. Ann Plast Surg 2004; 52:246–52.

    Article  PubMed  Google Scholar 

  23. Metcalfe KA, Esplen MJ, Goel V, Narod SA. Psychosocial functioning in women who have undergone bilateral prophylactic mastectomy. Psychooncology 2004; 13:14–25.

    Article  PubMed  Google Scholar 

  24. King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 2001; 286:2251–6.

    Article  PubMed  CAS  Google Scholar 

  25. Jernström H, Lubinski J, Lynch HT, et al. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2004; 96:1094–8.

    PubMed  Google Scholar 

  26. Agnantis NJ, Paraskevaidis E, Roukos DH. Carcinogenesis of breast bancer: Advances and applications. Gastric Breast Cancer 2004;3:5–14. (Accessed August 20, 2004, at http://www.gastricbreastcancer.com/breastcancer_abs.asp.)

  27. Schrag D, Kuntz KM, Garber JE, Weeks JC. Decision analysis – effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 and BRCA2 mutations. N Engl J Med 1997; 336:1465–71.(Erratum, N Engl J Med 1997; 337:434).

    Article  PubMed  CAS  Google Scholar 

  28. Rebbeck TR, Levin AM, Eisen A, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999; 91:1475–9.

    Article  PubMed  CAS  Google Scholar 

  29. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002; 346:1616–22.

    Article  PubMed  Google Scholar 

  30. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002; 346:1609–15.

    Article  PubMed  Google Scholar 

  31. Garber JE, Hartman AR. Prophylactic oophorectomy and hormone replacement therapy: protection at what price? J Clin Oncol 2004; 22:978–80.

    Article  PubMed  Google Scholar 

  32. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288:321–33.

    Article  Google Scholar 

  33. Roukos DH, Kappas AM. Risks and benefits of risk-reducing surgery in inherited breast and gastric cancer susceptibility. Gastric Breast Cancer 2002; 1:65–7.

    Google Scholar 

  34. Gswind A, Fischer OM, Ullrich A. The discovery of receptors tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004; 4:361–70.

    Article  CAS  Google Scholar 

  35. van de Vijver MJ, He YD, van ’t Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347:1999–2009.

    Article  PubMed  CAS  Google Scholar 

  36. Roukos DH, Pavlidis N, Agnantis NJ. Gene-expression profile: the future in the outcome prediction and treatment of breast cancer. Gastric Breast Cancer2003;2:5–8. (Accessed August 18, 2004 at http://www.gastriccancer.net/Gene–Expression_abs.asp.)

  37. Klaren HM, van’t Veer LJ, van Leeuwen FE, Rookus MA. Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation. J Natl Cancer Inst 2003; 95:941–7.

    Article  PubMed  Google Scholar 

  38. Roukos DH, Agnantis NJ, Paraskevaidis E, Kappas AM. Challenges in surgical preventive decision for BRCA1/BRCA2-mutation carriers. Gastric Breast Cancer 2002; 1:68–70.

    Google Scholar 

  39. Roukos DH, Agnanti NJ, Paraskevaidis E, Kappas AM. Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol 2002; 9:941–3.

    PubMed  Google Scholar 

  40. Roukos DH. Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis—Invited Critique. Arch Surg 2003; 138:1329.

    Article  Google Scholar 

  41. Roukos DH, Kappas AM, Agnantis NJ. Perspectives and risks of breast-conservation therapy for breast cancer (Editorial). Ann Surg Oncol 2003 Aug; 10:718–21.

    Article  PubMed  Google Scholar 

  42. Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004; 22:2328–35.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Ioannina University School of Medicine, Ioannina, GR, 45110, Greece

    Niki J. Agnantis MD, PhD

  2. Department of Gynecology and Obstetrics, Ioannina University School of Medicine, Ioannina, GR, 45110, Greece

    Evangelos Paraskevaidis MD

  3. Department of Surgery, Ioannina University School of Medicine, Ioannina, GR, 45110, Greece

    Dimitrios Roukos MD

  4. Department of Surgery, Ioannina University School of Medicine, Ioannina, GR, 45110, Greece

    Dimitrios Roukos MD

Authors
  1. Niki J. Agnantis MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Evangelos Paraskevaidis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dimitrios Roukos MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dimitrios Roukos MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Agnantis, N.J., Paraskevaidis, E. & Roukos, D. Preventing Breast, Ovarian Cancer in BRCA Carriers: Rational of Prophylactic Surgery and Promises of Surveillance. Ann Surg Oncol 11, 1030–1034 (2004). https://doi.org/10.1245/ASO.2004.09.910

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1245/ASO.2004.09.910

Search

Navigation